STEP Programme

Timeline

1. 2021 · New England Journal of Medicine (STEP-1 lead publication)
   STEP

   Randomised trial programme evaluating once-weekly subcutaneous Semaglutide for weight management in adults with overweight or obesity, across multiple populations and comparators (STEP-1 through STEP-8).

2. 2021 · New England Journal of Medicine
   STEP-1

   68-week randomised double-blind placebo-controlled Phase 3 trial of once-weekly subcutaneous Semaglutide 2.4 mg in 1,961 adults with overweight or obesity without diabetes (Wilding et al. 2021).

3. 2021 · Lancet
   STEP-2

   68-week randomised placebo-controlled Phase 3 trial of Semaglutide 2.4 mg and 1.0 mg vs placebo in adults with overweight/obesity and T2D (Davies et al. 2021).

4. 2021 · JAMA
   STEP-3

   68-week randomised placebo-controlled Phase 3 trial of Semaglutide 2.4 mg as adjunct to intensive behavioural therapy in adults with overweight/obesity (Wadden et al. 2021).

5. 2021 · JAMA
   STEP-4

   68-week Phase 3 trial with 20-week Semaglutide 2.4 mg run-in and randomised continuation vs placebo, characterising maintenance and post-withdrawal weight regain (Rubino et al. 2021).

6. 2022 · Nature Medicine
   STEP-5

   104-week randomised double-blind placebo-controlled Phase 3 trial of Semaglutide 2.4 mg in adults with overweight/obesity (Garvey et al. 2022).

7. 2022 · JAMA
   STEP-8

   68-week randomised head-to-head Phase 3 trial of once-weekly Semaglutide 2.4 mg vs once-daily Liraglutide 3.0 mg in adults with overweight/obesity (Rubino et al. 2022).

Compounds

• Semaglutide

Mechanisms

• GLP-1 Receptor

Research applications

• Chronic weight management research
• Behavioural intervention overlays

Comparisons

• Semaglutide vs Retatrutide

  Side-by-side comparison of Semaglutide (GLP-1 mono-agonist) and Retatrutide (GLP-1/GIP/GCG triple agonist) — receptor coverage, structural chemistry, pharmacokinetics, evidence maturity and research applications.

• Semaglutide vs Tirzepatide

  Comparison of Semaglutide (GLP-1 mono-agonist) and Tirzepatide (GLP-1/GIP dual agonist) — receptor coverage, structural chemistry, pharmacokinetics and the published head-to-head evidence base.

• Semaglutide vs Liraglutide

  Comparison of Semaglutide (once-weekly, C18 di-acid) and Liraglutide (once-daily, C16 mono-acid) — shared receptor pharmacology, differing acylation chemistry, pharmacokinetics and evidence base.